HAM
VRTX icon

Highstreet Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Highstreet Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$616K Buy
2,815
+670
+31% +$136K 0.03% 213
2019
Q3 		$363K Hold
2,145
– – 0.02% 227
2019
Q2 		$393K Buy
+2,145
New +$375K 0.02% 226

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Highstreet Asset Management's VRTX Position: Q4 2019 in Review

Highstreet Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 31% in Q4 2019, buying an estimated $136K and bringing the position to 2,815 shares worth $616K. The position accounts for 0.03% of the portfolio, ranked #213.

Highstreet Asset Management first reported a position in VRTX in Q2 2019 and has held it in 3 quarters since. 814 funds tracked by Wall St. Rank hold VRTX as of Q4 2019.

  • Highstreet Asset Management held 2,815 shares of Vertex Pharmaceuticals worth $616K as of Q4 2019.
  • Highstreet Asset Management bought 670 Vertex Pharmaceuticals shares in Q4 2019, an estimated $136K.
  • Vertex Pharmaceuticals made up 0.03% of Highstreet Asset Management's portfolio in Q4 2019, its #213 holding.
  • Highstreet Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2019 and has held it in 3 quarters since.
  • 814 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2019.

Based on Highstreet Asset Management's 13F filing for Q4 2019, filed 12 Feb 2020.